Mesenteric Venous Thrombosis Clinical Trials

Find Mesenteric Venous Thrombosis Clinical Trials Near You

Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Acute Femoropopliteal DVT (DEXTERITY-AFP)

Status: Recruiting
Location: See all (17) locations...
Intervention Type: Combination product
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

This is a study of a medical procedure that utilizes a commercially available catheter (the Bullfrog® Micro-Infusion Device) to locally deliver a commercially available anti-inflammatory drug (dexamethasone sodium phosphate injection) around the deep veins after DVT recanalization, where DVT symptoms were present for up to 14 days prior to recanalization. The goal of the study is to see if local anti-inflammation helps prevent re-thrombosis of the blood vessel and improvement in symptoms for up to 24 months after the initial DVT recanalization procedure.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 89
Healthy Volunteers: f
View:

• Provision of signed and dated informed consent form prior to receiving any non-standard of care, protocol-specific procedures.

• Stated willingness to comply with all study procedures including completion of questionnaires and follow-up visits and availability for the duration of the study.

• Male or female, aged 18 to 89 years.

• For females of reproductive potential: use of highly effective contraception (abstinence is acceptable) for at least 1 month prior to study treatment (unless they had given birth within the 1 month prior to study treatment), and agreement to use such a method for at least 30 days after study treatment.

• Onset of acute DVT symptoms of 14 days or less prior to initial intervention in the study limb.

• Ability to take oral medication and be willing to adhere to the prescribed anti-coagulant regimen.

• Post-procedural prescription for at least 28 days low molecular weight heparin followed by therapeutic anticoagulant of investigator's choice for 12 months minimum as part of post-interventional medication regimen.

• Minimum of 28 days of prescribed antiplatelet agent (aspirin or P2Y12 inhibitor) for patients receiving stents.

• DVT located in any of the major femoropopliteal veins (common femoral, femoral, and/or popliteal above the tibial plateau), with possible extension downstream into the iliac veins.

⁃ Successful recanalization of the target vein with removal of acute thrombus.

Locations
United States
California
Providence St. Joseph Hospital
RECRUITING
Orange
Connecticut
Vascular Care Connecticut
RECRUITING
Darien
Florida
HCA Florida JFK Hospital
RECRUITING
Atlantis
Baptist Health
RECRUITING
Jacksonville
University of South Florida
RECRUITING
Tampa
Georgia
Piedmont Heart Institute
RECRUITING
Atlanta
Louisiana
CIS Clinical Research
RECRUITING
Houma
Maryland
Medstar Health Research Institute
RECRUITING
Hyattsville
North Carolina
NC Heart and Vascular Research
RECRUITING
Raleigh
New Jersey
Englewood Health
RECRUITING
Englewood
New York
Stony Brook University Hospital
RECRUITING
Stony Brook
Ohio
OhioHealth Research Institute
ACTIVE_NOT_RECRUITING
Columbus
Oklahoma
St John Health System
ACTIVE_NOT_RECRUITING
Bartlesville
Pennsylvania
Allegheny General Hospital
RECRUITING
Pittsburgh
Virginia
Sentara Norfolk General Hospital
RECRUITING
Norfolk
Other Locations
Ireland
Galway University Hospital
COMPLETED
Galway
United Kingdom
Guy's and St. Thomas Hospital
ACTIVE_NOT_RECRUITING
London
Contact Information
Primary
Kirk Seward, PhD
kseward@mercatormed.com
510-614-4550
Time Frame
Start Date: 2021-10-29
Estimated Completion Date: 2028-02-01
Participants
Target number of participants: 80
Treatments
Experimental: Treatment
Sham_comparator: Control
Related Therapeutic Areas
Sponsors
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Leads: Mercator MedSystems, Inc.

This content was sourced from clinicaltrials.gov